GlassScriptPhysician profile
Lakshmi Boyapati
NPI 1205290194
$2,477.64
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $337 · 2021: $546 · 2022: $658 · 2023: $340 · 2024: $63.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $318.65 | 2019-2023 | Padcev, Adcetris |
| Lilly USA, LLC | $262.23 | 2021-2022 | |
| Pfizer INC. | $172.77 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $156.31 | 2020-2023 | Tagrisso |
| Genentech USA, INC. | $140.00 | 2019-2024 | Polivy |
| Amgen INC. | $135.34 | 2021-2023 | |
| Janssen Biotech, INC. | $134.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $93.39 | 2020-2021 | |
| Genzyme Corporation | $92.15 | 2020-2023 | |
| Incyte Corporation | $88.56 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Eisai INC. | $80.09 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $77.51 | 2020-2022 | |
| Puma Biotechnology, INC. | $72.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.53 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $61.81 | 2020-2021 | |
| Celgene Corporation | $51.52 | 2019-2023 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $38.19 | 2019-2024 | Fruzaqla |
| G1 Therapeutics, INC. | $37.19 | 2022-2023 | Cosela |
| Emd Serono, INC. | $28.90 | 2022 | |
| Gilead Sciences, INC. | $26.20 | 2023 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $25.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.99 | 2023 | Libtayo |
| Exelixis INC. | $24.41 | 2020 | |
| Alnylam Pharmaceuticals INC. | $22.68 | 2023 | Amvuttra |
| Dova Pharmaceuticals | $21.72 | 2021 | |
| Array Biopharma INC | $17.82 | 2022 | |
| Daiichi Sankyo INC. | $17.60 | 2019 | |
| Foundation Medicine, INC. | $14.83 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.82 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmi Boyapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.